Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384061 | 0.81 | GPR119 (0.63) | GPR119ACHEGBA1TLR9KIT | |
| SCHEMBL18282621 | 0.78 | JAK2 (0.49) | GPR119ACHELMNAMAPTGBA1 | |
| SCHEMBL2385264 | 0.78 | GPR119 (0.59) | GPR119ACHETLR9 | |
| SCHEMBL18282571 | 0.76 | NAMPT (0.43) | GPR119SMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL18282634 | 0.76 | GPR119 (0.47) | GPR119ACHESMN1; SMN2MEN1KMT2A | |
| SCHEMBL18282631 | 0.75 | JAK2 (0.49) | GPR119ACHEGBA1KITNAMPT | |
| SCHEMBL2386443 | 0.74 | GPR119 (0.68) | GPR119ACHETLR9KIT | |
| SCHEMBL20423837 | 0.74 | ACHE (0.47) | GPR119ACHEMEN1KMT2AGBA1 | |
| SCHEMBL2384235 | 0.73 | POLB (0.48) | GPR119SMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL13587106 | 0.73 | MAPT (0.63) | GPR119SMN1; SMN2MEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | GPR119 686/4885ACHE 3013/4885SMN1; SMN2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.